Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.73 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5346660 | 0.87 | MAOA (0.72) | MAOAPPARGNPC1CYP1A1CYP1A2 | |
| SCHEMBL7333754 | 0.85 | MAOA (1.00) | MAOAPPARGNPC1MEN1KMT2A | |
| SCHEMBL11029659 | 0.84 | POLB (0.79) | MAOAPOLB | |
| SCHEMBL27244497 | 0.84 | PPARG (0.54) | MAOAPPARGPOLBNPC1ADORA3 | |
| SCHEMBL29908967 | 0.84 | PPARG (0.54) | MAOAPPARGPOLBNPC1ADORA3 | |
| SCHEMBL31060715 | 0.81 | MAOA (0.68) | MAOAPPARGPOLBNPC1MEN1 | |
| SCHEMBL11029477 | 0.81 | MAOA (0.68) | MAOAPPARGPOLBNPC1MEN1 | |
| SCHEMBL4914778 | 0.79 | MAOA (0.61) | MAOAPOLBNPC1L3MBTL1RAB9A | |
| SCHEMBL5349187 | 0.79 | MAOA (0.76) | MAOAPOLBNPC1RAB9A | |
| SCHEMBL11026526 | 0.79 | MAOA (0.65) | MAOANPC1MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846749-B2 | Anticancer-aiding compound, method for preparing the same, anticancer-aiding composition containing the same and method for reducing anticancer drug resistance using the same | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2014-09-30 | — | — | US | disclosed |
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-07-26 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | ABCC1, ANXA1, ANXA5 | MAOA 4052/4885PPARG 4701/4885POLB 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.